Rhythm and Conduction Disorders in Patients Receiving Ibrutinib

ANTINEOPLASTIC THERAPY COMPLICATIONS , , , , , ,

EI Emelina1, GE Gendlin1, IG Nikitin1, EA Dmitrieva2, EA Nikitin2, VV Ptushkin2

1 NI Pirogov Russian National Research Medical University, 1 Ostrovityanova str., Moscow, Russian Federation, 117997

2 SP Botkin Municipal Clinical Hospital, 5 2-i Botkinskii pr-d, Moscow, Russian Federation, 125284

For correspondence: Prof. Gennadii Efimovich Gendlin, MD, PhD, 1 Ostrovityanova str., Moscow, Russian Federation, 117997; e-mail: rgmugt2@mail.ru

For citation: Emelina EI, Gendlin GE, Nikitin IG, et al. Rhythm and Conduction Disorders in Patients Receiving Ibrutinib. Clinical oncohematology. 2019;12(2):220–30.

DOI: 10.21320/2500-2139-2019-12-2-220-230

ABSTRACT

Aim. Early diagnosis and treatment of rhythm and conduction disorders in patients receiving ibrutinib.

Materials & Methods. The trial included 206 patients with indications for ibrutinib, 193 of them are at different stages of treatment from 1.5 to 51 months. The trial enrolled the patients with chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia, aged 59 to 72 years (with median age of 66 years): 70 women aged 54 to 71 years (with median age of 64 years), and 123 men aged 60 to 72 years (with median age of 66 years). For early detection of rhythm and conduction disorders all the patients received ECG monitoring and 24-hour Holter ECG monitoring.

Results. Atrial fibrillation (AF) was identified in 21 (12 %) patients during ibrutinib therapy period of 1 to 24 months. Most often AF is registered within the first 6 months of ibrutinib therapy. Before its administration 18 (10.5 %) patients had history of prior AF. Thus, a total of 39 ibrutinib recipients with AF are followed-up. According to CHA2DS2-VASc 27 (69 %) of them have an indication for anticoagulant treatment. Severe atrioventricular block was diagnosed in 2 (1 %) patients that necessitated a pacemaker. In 2 (1 %) female patients severe supraventricular tachycardia with up to 295 BPM was registered which required ablation. In a patient with permanent atrial fibrillation rhythm pauses were identified and a pacemaker was installed.

Conclusion. The presence of AF in ibrutinib recipients is not a withdrawal criterion and does not require ibrutinib therapy to be discontinued. Anticoagulants were administered to patients with AF according to existing guidelines in compliance with CHA2DS2-VASc which had to be approached with caution and required dynamic monitoring of patients. Severe rhythm and conduction disorders in ibrutinib recipients arise in rare cases (2 %). Such patients require cardiac surgery with subsequent ibrutinib treatment without dose reduction. Timely diagnosis and the correction of rhythm and conduction allow to avoid changing of antitumor therapy plan.

Keywords: ibrutinib, chronic lymphocytic leukemia, atrial fibrillation, atrioventricular block, rhythm pauses, supraventricular tachycardia, pacemaker installation, ablation.

Received: October 30, 2018

Accepted: February 8, 2019

Read in PDF 

REFERENCES

  1. Gribben JG, Bosch F, Cymbalista F, et al. Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. Br J Haematol. 2018;180(5):666–79. doi: 10.1111/bjh.15080.

  2. Zamorano JL, Lancellotti P, Munoz RD, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801. doi: 10.1093/eurheartj/ehw211.

  3. Brown JR, Moslehi J, O’Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796–805. doi: 10.3324/haematol.2017.171041.

  4. Gustine JN, Meid K, Dubeau TE, et al. Atrial fibrillation associated with ibrutinib in Waldenstrom macroglobulinemia. Am J Hematol. 2016;91(6):E312–3. doi: 10.1002/ajh.24366.

  5. Lee HJ, Chihara D, Wang M, et al. Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma. Leuk Lymphoma. 2016;57(12):2914–6. doi: 10.3109/10428194.2016.1169408.

  6. Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138–40. doi: 10.1182/blood-2016-05-712828.

  7. Mulligan SP, Ward CM, Whalley D, et al. Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders. Br J Haematol. 2016;175(3):359–64. doi: 10.1111/bjh.14321.

  8. Chai KL, Rowan G, Seymour JF, et al. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib. Leuk Lymphoma. 2017;58(12):2811–4. doi: 10.1080/10428194.2017.1315115.

  9. Thompson PA, Levy V, Tam CS, et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016;175(3):462–6. doi: 10.1111/bjh.14324.

  10. Клинические рекомендации: «диагностика и лечение фибрилляции предсердий», 2017г. Под ред. А.Ш. Ревишвили, Ф.Г. Рзаева и др. [электронный документ]. Доступно по: webmed.irkutsk.ru/doc/pdf/af.pdf. Ссылка активна на 30.10.2018.

    [Revishvili ASh, Rzaeva FG, et al. (eds). Klinicheskie rekomendatsii: “diagnostika i lechenie fibrillyatsii predserdii”. (Clinical Guidelines “Diagnosis and treatment of atrial fibrillation”.) [Internet] Available from: webmed.irkutsk.ru/doc/pdf/af. (accessed 30.10.2018) (In Russ)]

  11. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962. doi: 10.1093/eurheartj/ehw210.

  12. Shanafelt TD, Parikh SA, Noseworthy PA, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017;58(7):1630–9. doi: 10.1080/10428194.2016.1257795.

  13. Wiczer TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1(20):1739–48. doi: 10.1182/bloodadvances.2017009720.

  14. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–93. doi: 10.1093/eurheartj/ehy136.

  15. Shah S, Norby FL, Datta YH, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018;2(3):200–9. doi: 10.1182/bloodadvances.2017010694.

  16. Lopez-Fernandez T, Canales M, Farmakis D, et al. Ibrutinib-Associated Atrial Fibrillation: A Practical Approach. Ann Hematol Oncol. 2018;5(4):1203. doi: 10.26420/annhematoloncol.2018.1203.

  17. Thorp BC, Badoux X. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management. Leuk Lymphoma. 2017;59(2):311–20. doi: 10.1080/10428194.2017.1339874.

  18. Mathur K, Saini A, Ellenbogen KA, Shepard RK. Profound Sinoatrial Arrest Associated with Ibrutinib. Case Rep Oncol Med. 2017;2017:1–3. doi: 10.1155/2017/7304021.

  19. Имбрувика® (инструкция по медицинскому применению). Джонсон & Джонсон (Россия). Доступно по: https://www.vidal.ru/drugs/imbruvica__43861. Ссылка активна на10.2018.

    [Imbruvica® (package insert). Johnson & Johnson (Russia). Available from: https://www.vidal.ru/drugs/imbruvica__43861. (accessed 30.10.2018) (In Russ)]